Proactive research analyst Emma Ulker discusses MaxCyte's (LON:MXCT) results for the year to December 2019.
Ulker says the firm delivered a consensus-beating 30% uplift in full-year 2019 revenues to US$21.6mln - underpinned by the release of milestone payments from its commercial partners as programmes advanced through clinical studies and by a 25% five-year revenue compound annualised growth rate (CAGR).